Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network.
Carla GaggianoDonato RiganteJosé Hernández-RodríguezAntonio VitaleMaria TarsiaAlessandra SorianoGiuseppe LopalcoFlorenzo IannoneMasen Abdel JaberRoberto GiacomelliEwa Więsik-SzewczykMarco CattaliniMicol FrassiMatteo PigaGaafar RagabJurgen SotaFiammetta ZunicaAlberto FlorisVito SabatoMohamed Tharwat HegazyOlga AraújoLaura PelegrínAlessandra FabbianiAlessandra RenieriSalvatore GrossoClaudia FabianiBruno FredianiClaudia FabianiPublished in: Therapeutic advances in musculoskeletal disease (2021)
R92Q patients showed a favourable response to ANA and CAN, particularly when the mutation segregated in a family member and when a relapsing-remitting disease course or TNF-α receptor-associated periodic syndrome (TRAPS) typical skin rash were observed. In the subgroup of patients not taking advantage of IL-1 blockage different molecular mechanisms underlying the autoinflammatory picture are likely to exist.